Chainlink has acquired Atlas to expand the multi-chain reach of Chainlink SVR, enabling DeFi protocols to recapture MEV, generate new revenue streams, and strengthenChainlink has acquired Atlas to expand the multi-chain reach of Chainlink SVR, enabling DeFi protocols to recapture MEV, generate new revenue streams, and strengthen

Chainlink Acquires FastLane’s Atlas To Expand SVR And Enhance Revenue Opportunities For DeFi

2026/01/23 15:13
3 min read
Chainlink Acquires FastLane’s Atlas To Expand SVR And Enhance Revenue Opportunities For DeFi

Chainlink, an oracle services provider, stated that it has acquired Atlas and integrated key members of the Atlas team from FastLane, consolidating a market-tested approach to order flow and value recapture within the Chainlink framework. Under the new arrangement, Atlas will operate solely in support of Chainlink SVR, which is described as the most widely adopted solution for oracle extractable value recapture. The transition includes a simplified migration process for current Atlas users, including those moving from the discontinued Atlas RedStone deployment.

Originally created by FastLane, Atlas allows decentralized finance protocols such as Compound and Venus to recover value by enabling application-specific order flow auctions, including those used for liquidation events. Its production-ready order flow system has now been incorporated into Chainlink SVR, a move intended to expand revenue opportunities across the decentralized finance (DeFi) sector by extending SVR functionality to additional blockchain environments. Chainlink SVR is currently operational on Arbitrum, Base, BNB Chain, Ethereum, and HyperEVM, with further network integrations planned for the future.

FastLane indicated that it chose to align Atlas’s ongoing development and long-term growth with Chainlink due to the network’s established reputation for security and operational reliability, supported by its decentralized oracle network infrastructure. Chainlink reports that its technology has facilitated more than $27 trillion in transaction value and underpins over 70 percent of the decentralized finance ecosystem.

Chainlink SVR is presented as a new class of oracle infrastructure designed to allow decentralized finance applications to reclaim Maximal Extractable Value generated through their reliance on Chainlink Price Feeds. This form of value, commonly labeled Oracle Extractable Value, represents a category of non-harmful MEV that typically arises during the liquidation of overcollateralized positions in DeFi lending platforms. SVR has been engineered specifically to capture this type of value by backrunning liquidation events and is structurally restricted from enabling frontrunning, sandwich strategies, or other forms of adversarial MEV behavior.

The solution has already been integrated by major DeFi protocols, including Aave and Compound, and has handled more than $460 million in liquidation volume while recovering over $10 million in Oracle Extractable Value. Funds reclaimed through SVR create an incremental revenue source for participating DeFi applications and are also used to reinforce the long-term economic model of the Chainlink Network through a predefined revenue-sharing arrangement. Chainlink’s acquisition of Atlas is positioned as a catalyst for accelerating SVR’s deployment across multiple blockchains, with the stated objective of broadening access to sustainable revenue opportunities throughout the decentralized finance sector.

FastLane is expected to continue operating as an independent entity while maintaining a strategic partnership with Chainlink to support the operation, maintenance, and wider adoption of Atlas. Current Atlas users are able to migrate to Chainlink SVR using published developer documentation and can obtain technical assistance during the transition process from Chainlink Labs. On Ethereum mainnet, Chainlink SVR continues to rely on Flashbots MEV-Share for its implementation, while Atlas is being used to extend SVR functionality to additional blockchain environments.

The post Chainlink Acquires FastLane’s Atlas To Expand SVR And Enhance Revenue Opportunities For DeFi appeared first on Metaverse Post.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26